Clinical Report: Assessing the Effectiveness of Tenecteplase in Community Settings
Overview
This study evaluates the effectiveness and safety of Tenecteplase (TNK) compared to alteplase in treating ischemic stroke in community settings. Results indicate differences in early reperfusion rates, door-to-needle times, and functional outcomes.
Background
Tenecteplase has emerged as a potential alternative to alteplase for thrombolysis in acute ischemic stroke (AIS). Understanding the real-world effectiveness of TNK is crucial for optimizing treatment strategies in community healthcare settings.
Data Highlights
Outcome
TNK
Alteplase
P-value
Early Reperfusion
14.8%
4.5%
0.008
Median DTN Time
34 min
45 min
<0.001
Good 90-day Functional Outcome (mRS 0-2)
61.8%
50.0%
0.044
Symptomatic ICH
8.5%
15.0%
0.030
Key Findings
TNK resulted in a higher rate of early reperfusion compared to alteplase (14.8% vs. 4.5%, p = 0.008).
The median door-to-needle time was significantly shorter for TNK (34 min) compared to alteplase (45 min, p < 0.001).
Good functional outcomes at 90 days (mRS 0-2) were more common in the TNK group (61.8%) than in the alteplase group (50.0%, p = 0.044).
Symptomatic intracranial hemorrhage rates were similar between TNK and alteplase, but overall ICH was less frequent with TNK (8.5% vs. 15.0%, p = 0.030).
TNK was administered at a dose of 0.25 mg/kg (max 25 mg), demonstrating safety and efficacy in a community setting.
Clinical Implications
Clinicians should consider the results when deciding on thrombolytic therapy for patients with AIS.
Conclusion
TNK 0.25 mg/kg IV shows potential as a treatment for AIS, with differences in early reperfusion and safety compared to alteplase.
